Description du projet
Un kit de dépistage sur le lieu d’intervention pour le pronostic précoce de la septicémie
La septicémie engendre une réponse inflammatoire systémique actionnée par les cytokines proinflammatoires et constitue la principale cause de décès dans les unités de soins intensifs des hôpitaux. Des biomarqueurs précoces de la maladie sont nécessaires pour permettre d’identifier le processus décisionnel concernant les patients immunodéprimés. Le développement d’un kit de dépistage sur le lieu d’intervention pour permettre un dépistage rapide et fiable des patients immunodéprimés à l’aide de biomarqueurs sanguins permettrait d’améliorer le pronostic précoce de la septicémie. Un produit de pronostic in vitro a récemment été développé. Il permet de détecter rapidement une altération précoce de l’activation de l’inflammasome NLRP3, comme biomarqueur de pronostic de la septicémie. Le projet SPEDI-TEST actuellement financé par l’UE entend démontrer la faisabilité technique et commerciale, et évaluer la nouvelle opportunité commerciale de l’introduction clinique de ce test innovant.
Objectif
Sepsis remains the leading cause of death in critical care units of Hospitals, affecting more that 18 million people worldwide and causes a systemic inflammatory response driven by the production of proinflammatory cytokines. Several studies have been conducted to find out whether data mining and machine learning could be used to identify patients at risk of sepsis. Although the currently available biomarkers can help shorten this decision process, there is still a need for additional early disease biomarkers that could anticipate the decision-making identifying immunocompromised septic patients. In this sense, ongoing efforts in the development of a point-of-care testing kit, enabling quick and reliable detection of immunocompromised patients by using blood biomarkers, will aid greatly the early prognosis of sepsis. In this scenario, the prognosis and therapy selection still remains a clinical decision by assessing the patient’s history, symptoms of infection, and development of acute organ dysfunction. Our group have determined under the ERC consolidator grant ref. 614578 (DangerATP) that during the initial 24 h of the inflammatory response in sepsis, monocytes from human septic patients present an early impairment of the activation of the NLRP3 inflammasome that is associated with higher late mortality. This group of septic patients was not identified with any of the clinical or biochemical determinations performed.
We have developed an in vitro prognostic (IVD) product for the fast detection in less than 4 hours of early impairment of the NLRP3 inflammasome activation, as a biomarker for the prognosis in sepsis. This IVD will be used in intensive care units and immunology units of hospitals. The objective of the action is to demonstrate the technical and commercial feasibility and evaluate the new business opportunity of introducing this novel IVD product.
Champ scientifique
- social sciencessociologydemographymortality
- medical and health sciencesclinical medicinecritical care medicine
- natural sciencescomputer and information sciencesdata sciencedata mining
- medical and health sciencesbasic medicineimmunology
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
Programme(s)
Régime de financement
ERC-POC - Proof of Concept GrantInstitution d’accueil
30120 Murcia
Espagne